- Global Pharma News & Resources

Interim analysis presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Non-peer reviewed | Randomised Controlled Trial | People

Immunotherapy for bowel cancer could change clinical practice

A large international trial involving UCL and University College London Hospitals NHS Foundation Trust (UCLH) has found that pembrolizumab, a form of immunotherapy, more than doubled the ‘progression free survival’ time of patients with a specific subtype of advanced bowel cancer, when compared with chemotherapy.

‘Progression free survival’ is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the progression-free survival is one way to see how well a new treatment works.

As part of an interim analysis of clinical trial data, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, researchers found patients who were treated with pembrolizumab (also known as Keytruda) had ‘progression-free survival’ of 16.5 months (on average), compared with 8.2 months for those who were treated with chemotherapy.

In addition, 11% of patients who were treated with pembrolizumab were also found to have a ‘complete response’ where their disease had disappeared from scans. Furthermore, in almost half the patients who had pembrolizumab (48.3%), their disease had not progressed after two years versus only a fifth of patients who had had chemotherapy (18.6%), which means the beneficial effects are also durable.

The trial’s UK Chief Investigator, Dr Kai-Keen Shiu, Honorary Associate Professor in Oncology at UCL Cancer Institute and Consultant Medical Oncologist at UCLH, said:  “This is the first randomised controlled study to show that first-line immunotherapy is significantly better than chemotherapy at shrinking metastatic bowel cancers with these specific DNA mutations, and delaying the time it takes for the cancer to progress.

“Whilst only around five per cent of advanced bowel cancer patients have these genetic mutations, they usually have a worse prognosis, and less response to chemotherapy and other targeted agents.

“The results from this trial really are game-changing and will almost certainly result in a paradigm shift in our current clinical practice.”

The ‘KEYNOTE-177’ Phase III clinical trial, funded by Merck & Co (known as MSD in the UK), recruited 307 patients with metastatic bowel cancer, who had specific DNA mutations known as microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR).

These genetic alterations result in cells being unable to repair themselves correctly if damaged, and when this happens, errors in the DNA accumulate which may cause cancer. MSI-H/dMMR can be hereditary (also known as Lynch Syndrome) or sporadic, and affected patients usually have a poor prognosis when the disease has spread to other organs.

The randomised controlled trial recruited patients from 23 countries who were put into two equally sized groups. One group (or arm) of patients received pembrolizumab every three weeks for up to 35 cycles of treatment (up to approximately two years), while the other group received standard chemotherapy combinations with cancer targeting drugs bevacizumab or cetuximab (the chemotherapy arm) every two weeks.

Post-treatment results

  • For patients treated with pembrolizumab, progression-free survival was 55.3% at 12 months and 48.3% at 24 months. This compared with 37.3% and 18.6% respectively, for those on chemotherapy.  
  • On average patients treated with pembrolizumab had a progression free survival of 16.5 months, compared with 8.2 months of chemotherapy – an improvement of 8.3 months. 
  • 11% of patients receiving pembrolizumab had a complete response (no detectable cancer), compared to 3.9% on chemotherapy.
  • 32.7% of patients on pembrolizumab had a reduction in tumour size (partial response), compared to 29.2% on chemotherapy.
  • And 30.9% of patients on pembrolizumab had stable disease compared with 42.2% on chemotherapy*.
  • Response with pembrolizumab was also longer lasting, with 83% of patients having a response longer than 2 years, compared with 35% of patients receiving chemotherapy. 
  • Severe treatment-related adverse events were also less common with pembrolizumab, 22%, whereas with chemotherapy this is 66%.

UCLH was one of the largest recruiters of patients for the trial with 18 participants from across England and 10 patients received pembrolizumab as first-line treatment.

Dr Shiu added: “The results of the KEYNOTE 177 trial have been keenly awaited by patients, clinicians and scientists alike. It is very encouraging that the side effects of pembrolizumab are significantly less than with chemotherapy, so not only the quantity but also the quality of life of these patients is better on immunotherapy.

“Some of my trial patients had a complete response to this therapy, are very well and have now been in remission for more than three years.

“There is ongoing collaborative research at UCL, UCLH and our research partners to further our understanding of why some patients benefit so much from immunotherapy whilst others do not.”

Pembrolizumab is a type of immunotherapy known as a check-point inhibitor and helps make cancer cells more vulnerable to attack by your body’s own immune system. It does this by blocking the activity of a molecule called PD-1, thereby allowing T cells (white blood cells that help your body fight disease) attack and kill tumours as they should.

Lead author Professor Thierry André, of the University of Sorbonne, France, said: “Pembrolizumab works in non-randomised studies in this group of patients with advanced disease. This randomised study demonstrates a huge benefit in first line with pembrolizumab and should be the new standard of care.” 

*These stability figures are accurate. Patients receiving immunotherapy usually either respond well and/or stabilise disease but then their disease does not usually progress or relapse for a long time.  Patients on chemotherapy are less likely to have good responses but more disease stabilisation. However, in the majority of all cases, the effect of chemotherapy doesn’t last as long unlike the durable benefits of immunotherapy.

Notes to Editors

For more information or to speak with the researchers, please contact Henry Killworth, UCL Media Relations. T: +44 (0) 207 6795296 E:

Bowel Cancer: Background

Bowel cancer, also known as colorectal cancer, is the 2nd to 3rd most common cancer in developed countries, with about 130,000/42,000 new cases and 50,000/16,000 deaths in the USA (Siegel et al 2017) and UK (CRUK 2017) respectively. There are one million new cases and 500,000 deaths worldwide each year. More males develop CRC, with age-standardised rates of 86.1 per 100,000 males compared to 56.9 per 100,000 female in the UK (CRUK 2017). The primary treatment for early stage bowel cancer is resectional surgery, which is possible in 80% of patients. Localised stage bowel cancer is diagnosed in 39% of patients, for which the 5‐year survival rate is 90%. The survival rate declines to 71% and 14% for patients diagnosed with regional lymph node and metastatic CRC (mCRC), respectively. Even after curative intent surgery up to half of patients subsequently develop incurable recurrent disease. Five year survival is approximately 14% for patients with metastatic disease.

Microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR)

Fifteen percent of all bowel cancer cases harbour mismatch repair deficiency (MMR-d/MSI-H) of which 12% are sporadic and 3% are hereditary cases. In early stage non-metastatic disease, this subgroup of bowel cancers is associated with reduced rates of recurrence and improved survival. Although only 5% of all mCRC cases are MMR-d/MSI-H, these patients paradoxically have worse survival than patients with MMR-proficient/Microsatellite Stable mCRC. This may change now with the advent of immunotherapy for these patients.

About UCL – London’s Global University

UCL is a diverse community with the freedom to challenge and think differently.

Our community of more than 41,500 students from 150 countries and over 12,500 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems.

We are consistently ranked among the top 10 universities in the world and are one of only a handful of institutions rated as having the strongest academic reputation and the broadest research impact.

We have a progressive and integrated approach to our teaching and research – championing innovation, creativity and cross-disciplinary working. We teach our students how to think, not what to think, and see them as partners, collaborators and contributors.  

For almost 200 years, we are proud to have opened higher education to students from a wide range of backgrounds and to change the way we create and share knowledge.

We were the first in England to welcome women to university education and that courageous attitude and disruptive spirit is still alive today. We are UCL.| Follow @uclnews on Twitter | Watch our YouTube channel | Listen to UCL podcasts on SoundCloud | Find out what’s on at UCL Minds | #MadeAtUCL

Find out how UCL is helping lead the global fight against COVID-19

Editor Details

  • Company:
    • London’s Global University
  • Name:
    • London’s Global University
Last Updated: 29-May-2020